Apeloa Pharmaceutical Co.,Ltd
000739
Rang in Aktien
#4338
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Aktienkurs
$3.13
Marktkapitalisierung
$3.63B
Veränderung (1 Tag)
-1.32%
Veränderung (1 Jahr)
46.73%
Land
CN
Handel Apeloa Pharmaceutical Co.,Ltd (000739)
Kategorie
Healthcare
P/B-Verhältnis für Apeloa Pharmaceutical Co.,Ltd (000739)
P/B-Verhältnis zum October 2026 TTM: 4.10
Laut den neuesten Finanzberichten und dem Aktienkurs von Apeloa Pharmaceutical Co.,Ltd beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 4.10. Am Ende des Jahres 2023 lag das P/B-Verhältnis bei 2.91.
P/B-Verlauf für Apeloa Pharmaceutical Co.,Ltd von 2000 bis 2026
P/B-Verhältnis zum Jahresende
| Jahr | P/B-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 4.10 | 47.08% |
| 2024 | 2.79 | -4.02% |
| 2023 | 2.91 | -36.30% |
| 2022 | 4.57 | -44.09% |
| 2021 | 8.17 | 30.79% |
| 2020 | 6.25 | 54.03% |
| 2019 | 4.06 | 55.35% |
| 2018 | 2.61 | 6.58% |
| 2017 | 2.45 | -25.52% |
| 2016 | 3.29 | -15.47% |
| 2015 | 3.89 | 8.52% |
| 2014 | 3.59 | 61.94% |
| 2013 | 2.21 | 84.56% |
| 2012 | 1.20 | -71.82% |
| 2011 | 4.26 | 43.16% |
| 2010 | 2.97 | -10.68% |
| 2009 | 3.33 | 131.56% |
| 2008 | 1.44 | -62.40% |
| 2007 | 3.82 | 20.96% |
| 2006 | 3.16 | 103.63% |
| 2005 | 1.55 | -23.64% |
| 2004 | 2.03 | -11.01% |
| 2003 | 2.29 | -41.50% |
| 2002 | 3.91 | -43.69% |
| 2001 | 6.94 | 17.81% |
| 2000 | 5.89 | 0.00% |
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/B-Verhältnis | P/B-Verhältnis-Differenz | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
